Dr. Abdulghani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4991 Route 42
Suite 8
Turnersville, NJ 08012Phone+1 856-740-9777Fax+1 856-740-9990
Education & Training
- New York Medical College at Westchester Medical CenterFellowship, Geriatric Medicine (Internal Medicine), 2003 - 2004
- Rutgers Health/New Jersey Medical SchoolResidency, Internal Medicine, 2000 - 2003
- Cairo University School of MedicineClass of 1996
Certifications & Licensure
- NY State Medical License 2004 - Present
- NJ State Medical License 2004 - 2025
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification athenaClinicals EHR, athenahealth, Inc, 2013
Publications & Presentations
PubMed
- 32 citationsEvaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasisAlice B. Gottlieb, Sewon Kang, Kenneth G. Linden, Mark Lebwohl, Alan Menter
Clinical Immunology. 2004-04-01 - 116 citationsPharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgarisAlice B. Gottlieb, Salman Masuda, Rallapalli Ramamurthi, Ahsan A. Abdulghani, Pat Romano
Journal of the American Academy of Dermatology. 2003-01-01 - 24 citationsClinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibodyAlice B. Gottlieb, Mark Lebwohl, Mark C. Totoritis, Ahsan A. Abdulghani, Steve R. Shuey
Journal of the American Academy of Dermatology. 2002-11-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: